Sprint Bioscience AB (publ) has licensed the global rights to its cancer program VADA (VRK1) to Day One Biopharmaceuticals Inc. The total potential value of the agreement amounts to US$ 316 million plus single-digit royalties on sales of a future drug...
This document is hosted externally.
Unless the owner has removed it from the web, you can access the full document via its original URL:
https://storage.mfn.se/7653819a-9f40-4d63-8c4e-f53e98e56f05/sprint-bioscience-licenses-the-vada-vrk1-program-to-day-one-biopharmaceuticals.pdfUnless the owner has removed it from the web, you can access the full document via its original URL:
See similar contracts (1)
Alternatively, you can try searching for similar contracts:
